Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mesoblast ADR Representing 10 Ord Shs MESO

Healthcare Biotechnology
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for... see more

Recent & Breaking News (NDAQ:MESO)

Recent Analysis Shows HudBay Minerals, Meridian Bioscience, ArQule, Mesoblast, Concho Resources, and Liberty Global Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire November 29, 2018

Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China

GlobeNewswire November 26, 2018

Mesoblast Reports First Quarter Ended September 30, 2018 Financial Results and Operational Highlights

GlobeNewswire November 15, 2018

Mesoblast Financial Results Webcast for Quarter Ended September 30, 2018

GlobeNewswire November 15, 2018

Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval

GlobeNewswire November 11, 2018

Mesoblast to Host Analyst Call on Results of End-Stage Heart Failure Trial Being Presented at 2018 American Heart Association Scientific Sessions

GlobeNewswire November 9, 2018

Mesoblast Expands Partnership With JCR Pharmaceuticals for Treatment of Wound Healing in Epidermolysis Bullosa

GlobeNewswire October 24, 2018

Investor Expectations to Drive Momentum within ChannelAdvisor, WideOpenWest, Arcos Dorados, Mesoblast, Ferrari N.V, and Weatherford International — Discovering Underlying Factors of Influence

GlobeNewswire October 22, 2018

Mesoblast and Tasly Pharmaceutical Group Complete Transaction for Strategic Cardiovascular Partnership in China

GlobeNewswire October 12, 2018

Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board

GlobeNewswire October 9, 2018

Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions

GlobeNewswire October 2, 2018

Mesoblast Heart Failure Cell Therapy for Children Featured at Regenerative Symposium for Congenital Heart Disease

GlobeNewswire September 25, 2018

Children Treated With Remestemcel-L Continue to Have Strong Survival Outcomes at Six Months in Mesoblast’s Phase 3 Trial for Acute Graft Versus Host Disease

GlobeNewswire September 20, 2018

Tasly Pharmaceutical Group Receives All Necessary Approvals for Transaction With Mesoblast

GlobeNewswire September 17, 2018

Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights

GlobeNewswire August 29, 2018

Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group

GlobeNewswire August 28, 2018

Analysis: Positioning to Benefit within Alamos Gold, Nomad Foods, MyoKardia, Mesoblast, Core-Mark Holding, and Jounce Therapeutics — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire August 21, 2018

Mesoblast Enters Into Strategic Cardiovascular Alliance for China With Tasly Pharmaceutical Group

GlobeNewswire July 17, 2018

Leading Commercial and Transactional Healthcare Executive Shawn Cline Tomasello Joins Mesoblast Board

GlobeNewswire July 11, 2018

Mesoblast Enters Into US$50M Financing with Novaquest Capital for Commercial Readiness of Remestemcel-l in the Treatment of Acute Graft Versus Host Disease

GlobeNewswire July 2, 2018